Pharma wrestles with Sunshine Act disclosures as initial phase ends

The first phase of Sunshine Act disclosures left drugmakers uneasy, Ed Silverman writes. Companies encountered formatting problems that led to the rejection of submissions and they experienced confusion about assigning financial values. Drugmakers are also worried about possible discrepancies in the second phase, which started this month and will require more specific reporting.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief: